Leap Therapeutics, Inc. (LPTX) Touches $6.68 Formed H&S; Kingfisher plc (LON:KGF) Covered By 9 Bullish Analysts Last Week

Among 28 analysts covering Kingfisher PLC (LON:KGF), 9 have Buy rating, 12 Sell and 7 Hold. Therefore 32% are positive. Kingfisher PLC had 257 analyst reports since July 23, 2015 according to SRatingsIntel. RBC Capital Markets upgraded the stock to “Sector Performer” rating in Friday, November 17 report. The stock of Kingfisher plc (LON:KGF) earned “Sell” rating by Haitong Securities on Tuesday, January 3. Bernstein maintained the stock with “Outperform” rating in Thursday, September 17 report. BNP Paribas maintained it with “Outperform” rating and GBX 380 target in Monday, April 4 report. The stock of Kingfisher plc (LON:KGF) has “Underperform” rating given on Monday, January 18 by RBC Capital Markets. The firm has “Outperform” rating given on Friday, September 1 by Credit Suisse. The rating was maintained by Barclays Capital on Thursday, March 24 with “Underweight”. The company was maintained on Tuesday, November 24 by Cantor Fitzgerald. The firm earned “Outperform” rating on Sunday, October 4 by Bernstein. The stock of Kingfisher plc (LON:KGF) has “Outperform” rating given on Friday, July 31 by Bernstein. See Kingfisher plc (LON:KGF) latest ratings:

02/01/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 325.00 New Target: GBX 345.00 Maintain
15/12/2017 Broker: JP Morgan Rating: Underweight Old Target: GBX 288.00 New Target: GBX 288.00 Maintain
22/11/2017 Broker: JP Morgan Rating: Underweight Old Target: GBX 288.00 New Target: GBX 288.00 Maintain
22/11/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 325.00 New Target: GBX 325.00 Maintain
22/11/2017 Broker: Jefferies Rating: Buy Old Target: GBX 310.00 New Target: GBX 400.00 Upgrade
17/11/2017 Broker: RBC Capital Markets Rating: Sector Performer Old Target: GBX 300.00 New Target: GBX 325.00 Upgrade
06/11/2017 Broker: Investec Rating: Sell Old Target: GBX 268.00 New Target: GBX 268.00 Maintain
06/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: GBX 410.00 New Target: GBX 410.00 Initiate
06/11/2017 Broker: JP Morgan Rating: Underweight Old Target: GBX 288.00 New Target: GBX 288.00 Maintain
06/11/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 325.00 New Target: GBX 325.00 Maintain

Leap Therapeutics, Inc. (LPTX) formed inverse H&S with $7.15 target or 7.00% above today’s $6.68 share price. Leap Therapeutics, Inc. (LPTX) has $82.53M valuation. The stock decreased 4.98% or $0.35 during the last trading session, reaching $6.68. About 41,367 shares traded. Leap Therapeutics, Inc. (NASDAQ:LPTX) has 0.00% since February 1, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock increased 1.56% or GBX 5.4 during the last trading session, reaching GBX 352.4. About 2.25 million shares traded. Kingfisher plc (LON:KGF) has 0.00% since February 1, 2017 and is . It has underperformed by 16.70% the S&P500.

Kingfisher plc, together with its subsidiaries, supplies home improvement services and products through a network of retail stores and other channels located primarily in the United Kingdom and continental Europe. The company has market cap of 7.59 billion GBP. The firm offers garden furnishing, exterior lighting, performance hand and power tools, heating and cooling systems, security and water treatment products, air treatment products, and communication products. It has a 13.45 P/E ratio. It also engages in the property investment, sourcing, finance, and IT services businesses.

Analysts await Leap Therapeutics, Inc. (NASDAQ:LPTX) to report earnings on February, 12. After $-0.73 actual earnings per share reported by Leap Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.48% negative EPS growth.